Yarrow Bioscience, Inc.
Close on Oct 19, 2026
- Market cap
- $17.14M
- P/E (TTM)
- –
- Dividend yield
- –
About Yarrow Bioscience
Pharmaceutical Preparations, SIC 2834
VYNE is a clinical-stage biopharmaceutical company that develops therapies for inflammatory and immune-mediated conditions with high unmet medical needs. The company focuses on small molecule bromodomain and extra-terminal domain BET inhibitors, specifically through its InhiBET platform. Its pipeline includes VYN202, an oral BD2-selective inhibitor under evaluation for various autoimmune and inflammatory disorders, and repibresib, a topical pan-bromodomain inhibitor. Because its drug candidates remain in clinical development, the company does not yet sell commercial products to end consumers, but its research targets patients afflicted with serious inflammatory conditions.
The company maintains no internal manufacturing facilities and relies entirely on third-party contract organizations to produce materials for preclinical and clinical testing. It holds exclusive global rights to its core BET inhibitor compounds, and its intellectual property encompasses granted patents and pending applications across numerous international jurisdictions, including the United States, Europe, the United Kingdom, Japan, and China. The provided text does not identify the location of the company's corporate headquarters or total employee headcount.
Summary of the business section of Yarrow Bioscience's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Yarrow Bioscience, Inc.
- Headquarters
- New Haven, CT
- Address
- 470 James Street, Suite 007 06513
- Phone
- (203) 433-7577
- Employees
- 10, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Baker Tilly US, LLP, Tewksbury, Massachusetts
Stock & identifiers
- Ticker
- YARW
- Exchange
- Nasdaq
- IPO date
- Jan 26, 2018
- Shares outstanding
- 3M, Aug 10, 2026
- Public float
- $32.00M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-50 reverse, Aug 13, 2026; 1-for-50 reverse, Jul 27, 2026; 1-for-18 reverse, Feb 13, 2023; 1-for-18 reverse, Feb 10, 2023; 1-for-4 reverse, Feb 16, 2021; 1-for-4 reverse, Feb 12, 2021
- SEC CIK
- 1566044
- CUSIP
- 92941V407
- ISIN
- US92941V4077
- EIN
- 45-3757789
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Rebecca Frey | Chief Executive Officer, Director | – |
| David Domzalski | PRESIDENT AND CEO, Director | 347,174 |
| Lori Payton | Chief Development Officer | – |
| Rachael Alford | Chief Operating Officer | – |
| Steven Ryder | Chief Medical Officer | – |
| Mutya Harsch | CHIEF LEGAL OFFICER AND GC | 95,918 |
| Iain Stuart | CHIEF SCIENTIFIC OFFICER | 95,944 |
| Mona Ashiya | Director | 33,287 |
| Capital GP X. LLC OrbiMed | Director | – |
| Genesis GP LLC OrbiMed | Director | – |
| Steven L. Hoerter | Director | – |
| Advisors Llc Orbimed | Director | 233,019 |
| Tyler Zeronda | Director | 74,918 |
| Peter B. Silverman | Director | – |
| William Richard White | Director | – |
| Sven Ante Lundberg | Director | – |
| Elisabeth Sandoval Little | Director | – |
| Steven L. Basta | Director | 853,942 |
| Patrick G. Lepore | Director | 51,472 |
| Sharon Barbari | Director | 75,000 |
| Christine Borowski | Director | – |
| Anthony D. Bruno | Director | 120,123 |
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had a total of 10 full-time employees.”
Corporate history
Events identified from SEC filings